Hi @DickyB, thanks for sharing the link of the Emergence presentation.
I'd like to quickly share my thoughts.
- I think the 10 minute rapid presentation suits LC. She was upbeat and positive and didn't waffle. - LC used the word "cure" many times, saying she is looking for 90-100% curative rates in the treatments they're developing. Is that potentially a signal? - LC described the sale of Yescarta from Kite to Gilead for $11B USD off the back of data from only 50 patients. To make a very rough comparable calculation, 11b USD / 0.62 = 17.6 b AUD / 8.5b SOI (including options) = approx. $2 AUD / share if Imugene were to sell azer-cel for a similar valuation. Azer-cel may potentially be worth more as an allogeneic treatment. - The last Vaxinia MAST data update was November 2023. This means we are due for 15+ months worth of new Vaxinia data which has undertaken significant dosage escalations (with no safety issues). We already know Imugene plan to open more expansion trials meaning they are seeing meaningful data. This excites me. - LC speaks of the potential for onCARlytics to open up the market to all CD19 targeted therapies. LC has publicly stated many times that US investors and BP are watching these results closely. LC privately told me, at an investor roadshow in 2023, she believes we can partner onCARlytics with multiple partners in the future. - Lastly, I'm thrilled to hear the RPA patient (my local hospital), the first Australian site and patient, has achieved a Complete Response. A heartwarming and lifesaving outcome for the patient and a fantastic result for Imugene.
Shareholders have had to endure a very slow and difficult period waiting for data. Although many company announcements barely move the SP dial (regional patents, First Patient Dosed, dose escalation cohort clearances), these are all part of Imugene executing a strategy which is paving the way for future value. LC herself said she was disappointed with the $360m market cap but expects we will return to the billions in the future. I agree with LC and will continue to maintain my holding. Wishing all holders the best of luck. For better or for worse, I believe 2025 will show us the data we have been waiting for, giving us the confirmation (or not) shareholders are seeking.
My opinions only.
DYOR. Chur. Shornbra
IMU Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)